Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV) for the month of December 2017, specifically dated December 18, 2017. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release issued on the same date (Exhibit 99.1) into the company's active Registration Statements on Forms F-3 and S-8.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a procedural filing referencing an external press release. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not disclose specific material changes to financial position or operations. It solely indicates the issuance of a press release on December 18, 2017, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, or unusual items are not detailed in this filing text. The document functions as a conduit to incorporate the attached press release (Exhibit 99.1) by reference, but the substance of that release is absent from the input.
Investor Verification Checklist
- Verify the actual content of the press release dated December 18, 2017 (Exhibit 99.1), as the filing text only references it.
- Confirm the registrant name is Galapagos NV, as the input metadata incorrectly listed "Lakefront Biotherapeutics NV."
- Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, etc.) for context on the incorporated information.
- Check subsequent filings for the financial metrics and operational updates likely contained in the missing press release.